Transcript Highlights:

• It requires physicians to obtain approval before providing certain services. prescribed treatment, test
• It doesn't prescribe a one-size-fits-all approach. fits all solution.

Bills: HB163, HB216, HB721, HB2035, HB2038, HB3057, HB3153, HB3233, HB3595, HB3801, HB3812, HB4076, HB4129, HB4377, HB4535, HB4666, HB4730, HB4743, HB4903, HB5149, HB5155, HB1534, HB163, HB216

Keywords: epinephrine, healthcare, emergency response, administration, medical policy, health care, itemized billing, patient rights, provider regulations, Texas Health and Safety Code, cost disclosure, insurance, benefit plan, administrators, chemical dependency, treatment facilities, minor admissions, parental notice, mental health, medical licensing

Transcript Highlights:

• Doing off-label prescribing or using stem cell therapy as in here.
• They can actually just go to the pharmacist and the pharmacist can write the script.
• And only because epinephrine pens, um, I checked with my Walmart pharmacist.
• I checked with my Walmart pharmacist. They do have what they call generic pens.
• generic</c><01:12:25.440><c> one</c><01:12:25.600><c> was</c> pharmacist said the generic one was pharmacist

Bills: HB0003, HB0117, HB0041

Keywords: pregnancy centers, abortion, pro-life, healthcare, women's rights, state regulation, civil rights, freedom of speech, informed consent, civil liability, coercion, healthcare rights, law enforcement, death benefits, retirement, survivor support, public safety, 916, all

Transcript Highlights:

• </c><00:08:06.400><c> GLP-1</c> of the 20,000 who were prescribed GLP-1 of the 20,000 who were prescribed
• </c><00:10:46.240><c> a</c> the individuals who were prescribed a the individuals who were prescribed
• Not a pharmacist.
• Uh my Not a pharmacist. Yeah. Okay.
• Next up are the independent pharmacists.

Keywords: 958, all

Summary: The Medicaid Oversight and Advisory Board met on February 23, 2026, approved the January 12 minutes, and then focused primarily on Kentucky Medicaid’s coverage and potential expansion of GLP-1 drugs, especially for weight loss. Department for Medicaid Services Commissioner Lisa Lee explained that Medicaid currently does not cover drugs for weight loss, anorexia, or weight gain, but the department had filed a regulation to remove that blanket exclusion so GLP-1s could be covered when used for an underlying health condition. She said the administrative regulation review subcommittee found the regulation deficient, and the co-chairs wanted the board to discuss the policy and financing implications before any change. DMS also said it would be open to adding caveats to ensure coverage would not extend to cosmetic weight loss alone. The department provided several data points on current utilization and spending. In 2025, Kentucky Medicaid paid for appetite-stimulating drugs such as Megestrol, Dronabinol, and Marinol, but did not pay for weight-loss drugs. For GLP-1s, DMS said coverage began in 2025 and is limited to FDA-approved medical conditions, with prior authorization requiring a type 2 diabetes diagnosis code and A1C documentation. DMS reported $234.6 million in GLP-1 spending in 2025 before rebates, about 240,931 prescriptions, and said GLP-1s accounted for 7.3% of pharmacy spend in 2024 and 8.3% in 2025. It also said there were 24,844 expansion members and 13,638 non-expansion members using GLP-1s, with spending of about $156 million and $78.5 million respectively, and that 10 pediatric weight-loss prescriptions were covered under EPSDT. The department said outcome analyses, including whether GLP-1 use reduces insulin or other diabetes treatment, are underway and should be completed in a couple of months. Members asked about cost, rebates, and whether the state should wait for more outcomes data before expanding coverage. DMS said average reimbursement to pharmacies was $975 per prescription and the average dispensing fee was $109; it also said 2025 rebate invoices totaled $90.8 million, with $7.6 million collected so far. Several members expressed concern about the high cost and the need to evaluate whether the drugs improve health outcomes before expanding access, while others noted the potential benefits for obesity and diabetes treatment. Some members also discussed whether GLP-1s are effectively being used for weight loss in diabetic patients and whether broader data collection should be used to assess long-term value. After the Medicaid discussion, Eli Lilly executive Tracy Sims presented on obesity as a chronic disease and the economic burden it creates in Kentucky. She said Kentucky’s adult obesity rate is a little over 37%, that obesity is linked to about 200 diseases, and that untreated obesity costs the state billions in GDP and hundreds of millions in state budget impact. She highlighted recent federal access programs for GLP-1s, including a Medicaid-related program that she said could lower the state share of a Zepbound prescription to about $71 per month after federal matching. No votes were taken on the GLP-1 policy question during the meeting, and the main action was the receipt of testimony and discussion of the department’s proposed regulatory change.

Transcript Highlights:

• It came from CMS, and it came from a prescribing clinical psychologist.
• who have to go through extra schooling in order to do any kind of prescribing.
• who have to go through extra schooling in order to do any kind of prescribing.
• Alejandro Amparan, who is with OSI, and he's a pharmacist, and Dr.
• So, Madam Chair and Senator, the pharmacist, Dr. Alejandro, would like to...

Summary: The committee first took up Senate Bill 20, a prior-authorization measure aimed at exempting certain medications and treatments for seriously mentally ill adults from repeat insurance prior authorization, while also extending prior authorization approvals to three years for chronic maintenance drugs. The sponsor described the bill as the latest in a series of bipartisan prior-authorization reforms and accepted an amendment from the Health Care Authority and the Office of the Superintendent of Insurance to apply the bill to adults only and to cover PBMs in the interagency purchasing collaborative. Supporters, including NAMI New Mexico and state health officials, argued the bill would reduce barriers to needed care, especially for mental health treatment. Opponents from health plans, PBMs, and insurers warned the bill was too broad, lacked clear definitions for serious mental illness and chronic conditions, created patient-safety concerns, and should have a shorter reauthorization period and later implementation date. After committee discussion, the sponsor agreed to work on a committee substitute, and the bill was rolled over for a later meeting. The committee then heard Senate Bill 53, the Chispa data privacy bill, which would impose broad limits on the collection, sale, and use of personal data, require opt-in consent for many uses, strengthen rights to access, correct, and delete data, and create enforcement mechanisms including a private right of action. Supporters from advocacy, women’s, behavioral health, reproductive health, and civil rights groups said the bill was needed to protect sensitive health and location data, prevent surveillance and criminalization, and give New Mexicans real control over their information. Business, technology, insurance, and hospital representatives opposed the bill, arguing it was more restrictive than other states’ privacy laws, would burden small businesses and health-related services, create compliance uncertainty, and risk limiting digital services and innovation. After extensive questioning about data breaches, opt-in consent, nonprofit exemptions, and the bill’s impact on businesses and health care access, a motion to table failed 5-4, and the committee then passed SB 53 on a 5-4 vote. The committee next heard Senate Bill 86, which updates the state’s harassment-by-telephone law to cover electronic communications such as social media, messaging apps, and email. The sponsor and a Las Cruces police chief said the change would modernize an outdated 1967 statute and help law enforcement address harassment and domestic violence through current technology. The bill drew support from the governor’s public safety advisor and the Greater Albuquerque Chamber of Commerce, and members asked a few clarifying questions about the wording. The committee approved SB 86 unanimously, 9-0. Finally, the committee began hearing Senate Bill 96, on regulated childcare zoning requirements, using a committee substitute. The sponsor and the Early Childhood Education and Care Department said the bill would reduce confusing zoning and fire-code barriers to opening or expanding child care homes and centers, helping address a statewide shortage of child care slots and supporting working families. The discussion began with the committee substitute and an explanation that the measure is intended to streamline local requirements and expand child care supply.

Transcript Highlights:

• A lot of times, they prescribe this; they need to get it that day.
• And he was told by the pharmacist that it's going to require a prior authorization.
• Their contracted pharmacies are a huge issue with regard to this bill. pharmacists or other authorized
• Members of the House Committee on Insurance, I'm a pharmacist, and I've worked in 340B hospitals since
• Third, it does not address the impact that 340B has on market consolidation, the prescribing patterns

Bills: HB712, HB722, HB946, HB1687, HB1809, HB1899, HB2528, HB2583, HB2741, HB2750, HB3021, HB3150, HB3265, HB3658, HB3812, HB3960, HB4392, HB4432

Keywords: prostate cancer, health benefit plans, insurance coverage, cost sharing, preventive health care, auto insurance, total loss evaluation, disclosure, insurance materials, vehicle appraisal, HB 946, Texas Insurance Code, automobile insurance claims, oral release, written release, settlement agreement, claim release, property damage, bodily injury, psychological injury

Transcript Highlights:

• It requires prescribers with an Arizona address on their DEA registration to register with the CSPMP.
• and pharmacists must query the CSPMP.
• Madam Chair, members, the Bliss Amendment dated February 16, 2026, at 3:41 p.m. sets the date prescribers
• This bill currently requires pharmacists to complete their required continuing education before renewing
• from making a therapeutic substitution for an opioid drug if a contracted licensed position has prescribed

Summary: The Special Committee on Health and Human Services heard a series of continuation and board-reform bills, beginning with core review measures to continue the Arizona Department of Economic Security, the State Board of Nursing, the Board of Occupational Therapy Examiners, the Regulatory Board of Physician Assistants, and the State Board of Pharmacy. HB 2728, HB 2729, HB 2730, HB 2731 as amended, and HB 2732 all received due-pass recommendations, with the physician assistant board bill amended to extend the board for four years rather than two. The committee then moved to reform bills affecting the nursing board and pharmacy board, as well as a reconsidered health plan drug-coverage bill. HB 2408, which would change nursing board complaint procedures, prioritize certain allegations, allow limited expungement of disciplinary records, and adjust evidentiary and liability standards, drew extensive testimony. Nursing board leadership opposed the bill, arguing it would weaken patient safety, raise the burden of proof, and erase useful disciplinary history, while supporters said it would improve fairness, reduce backlog, and give nurses a second chance for non-patient-safety-related issues. After debate, the committee adopted an amendment and advanced the bill on a 7-4-1 vote. HB 2434, updating the controlled substances prescription monitoring program and related reporting and confidentiality rules, and HB 2733, changing pharmacy continuing education timing, delivery rules, and ownership-transition procedures, both passed unanimously after amendments. The committee also reconsidered HB 2725, which would limit access contractors’ use of therapeutic substitution and utilization controls for certain non-opioid drugs. Access and health plan representatives warned the bill was too broad and could significantly increase costs by affecting many drug classes, while the sponsor said the amendment was intended to address those concerns and preserve the policy goal. After the amendment was adopted, the bill failed on a 6-? vote and did not receive a due-pass recommendation. The chair then announced the committee was done hearing House bills and adjourned, with Senate bills expected in a later meeting.

Transcript Highlights:

• </c><00:15:36.800><c> for</c> drug that my doctor has prescribed for drug that my doctor has prescribed
• It can force people back to their prescriber to find a different medication, which can take months to
• Uh, it's seamless to the pharmacist and the patient.
• Um, we also have pharmacists on staff whose job it is to make sure that we're providing care.
• Pharmacists are needed to run this program. Safety is our top priority in everything we do.

Keywords: 1183, house

Transcript Highlights:

• UNDER MEDICAID WE HAVE A TEAM OF PHARMACISTS AND PHYSICIANS WHO SET THE PREFERRED DRUG LIST AND WE GET
• AND UNDER THAT BILL WE ALLOWED A PHYSICIAN OR OSTEOPATHIC PHYSICIAN TO COLLABORATE WITH A PHARMACIST
• TO SET UP A PROTOCOL THAT ALLOWS THE PHARMACIST TO CHANGE MEDICATION TO TRY VARIOUS MEDICATIONS FOR
• DAVID ALLEN WITH THE FLORIDA SOCIETY OF HEALTH PHARMACISTS. WAVES IN OPPOSITION, THANK YOU.
• THESE CONDITIONS WERE DEEMED TO BE SIMPLE ENOUGH TO ALLOW PHARMACISTS IN COLLABORATION WITH PHYSICIANS

Keywords: 999, senate, all

Transcript Highlights:

• And so the question then begs is, well, if there's less prescribed opioids out there...
• There's less prescribed opioids out there. And so why aren't the overdoses going down?
• The first is the average number of opioid pills prescribed at discharge.
• They were prescribing 36 pills before the Billion Pill Pledge Program, before we got started.
• Now they're prescribing about 13. Next metric is how many of those pills are used?

Summary: The committee first approved the minutes and then heard a detailed annual presentation from Dr. Thomas Arnold, chair of the Maternal Mortality Review Committee, on maternal mortality trends and review findings. He explained the committee’s structure, the de-identified review process, and the distinction between pregnancy-associated and pregnancy-related deaths. He said national maternal mortality has declined from its 2021 peak, but mental health conditions, substance use, overdose, suicide, cardiovascular disease, hemorrhage, infection, and embolism remain major causes. He emphasized that many deaths are preventable, with especially high rates among non-Hispanic Black women and in the American Indian/Alaska Native population, and noted that a large share of deaths occur after 42 days postpartum. Committee members asked about suicide, domestic abuse, pregnancy testing in unexplained deaths, and the role of home births and midwife training. Dr. Arnold said the committee is adding a caseworker, exploring post-mortem pregnancy testing in suspicious cases, and working with coroners and forensic officials; he also said home births and untrained midwifery pose safety concerns and that better public education and facility-based care are important. The committee then heard from State Fire Marshal Dr. Matt Clark on cigarette ignition propensity standards and fire prevention. He recommended updating North Dakota’s cigarette ignition legislation to the current national standard and also considering legislation requiring fast-breakaway oxygen tubing, citing fatal fires involving smoking around home oxygen. He explained that his office verifies manufacturer testing and maintains certification for cigarettes sold in the state, but does not itself conduct the testing. Members asked about implementation, cost, and whether the standards apply in tribal communities; Clark said he would follow up with cost information and additional details, and that he had not seen evidence of a major issue on tribal lands but would look further. Christine Greff of the Department of Health and Human Services presented the North Dakota Stroke System of Care report. She described the statewide network of two comprehensive stroke centers, four primary stroke centers, and 30 acute stroke-ready hospitals, along with the stroke registry and quality-improvement efforts. She reported that most strokes are ischemic, that the median stroke patient age is 71.5, and that common risk factors include hypertension, dyslipidemia, obesity, and diabetes. She highlighted improvements in door-to-CT, thrombolytic treatment times, dysphagia screening, EMS pre-notification, and interfacility transfer performance, and said new priorities include hemorrhagic stroke quality measures and standardized EMS stroke screening tools. Members asked about the VA hospital’s participation, and Greff said she would pursue outreach. After a break, the committee heard testimony from Taha Khan of Vertex Pharmaceuticals as part of the prior authorization study, focused on non-opioid pain treatment. He argued that prior authorization can delay access to acute pain treatment and may push patients toward opioids, especially in the critical 24- to 72-hour post-discharge window. He cited data showing that even short opioid exposure can increase the risk of long-term use and said prior authorization is often a barrier for physicians and patients. Khan recommended open access with a quantity limit rather than prior authorization, suggesting a 14-day limit supported by the product’s data and an episode-of-care approach. Members asked about dental use, payer discussions, and cost; he said the product’s wholesale acquisition cost is about $16.10 per tablet, with patient assistance available, and that he would follow up on payer and comparison-cost questions.

Transcript Highlights:

• It also provided some clarity for our independent pharmacists.
• So you're a pharmacist, Representative Chassion.
• And so I know this is a battle between retail pharmacists and independent pharmacists, but it reminds
• And so I know this is a battle between retail pharmacists and independent pharmacists, but it reminds
• Woodard is here; he's actually a pharmacist that I go to.

Summary: The committee first adopted the minutes from several prior 2025 meetings, then took up HB 574 by Rep. Spell, which updates the names of two organizations on the Mental Health Advocacy Service Board of Trustees. Rep. Spell explained it as a technical cleanup bill to correct the names of the Louisiana Mental Health Association and the Louisiana State Medical Society so the board’s membership records match current organization names. With no objections, HB 574 was reported favorably. The committee then heard HB 486, also by Rep. Spell, to join the Psychology Interjurisdictional Compact (PsyPact) and allow Louisiana psychologists to provide telepsychology and temporary in-person services across state lines. Rep. Spell and PsyPact representatives said the compact would expand access to mental health care, especially in rural areas, while maintaining standards and disciplinary oversight. The committee adopted amendments on fees and the effective date, and HB 486 was reported favorably with amendments. HB 198 by Rep. Eccles proposed a Medicaid reimbursement methodology for ambulatory surgical centers, using a Medicare-based rate to improve access for Medicaid patients needing specialty procedures. Amendments were adopted to add ophthalmology-related services and to cap reimbursement at the lesser of the outpatient hospital rate or 100% of the Medicaid rate, along with a technical amendment to address the fiscal note. Supporters from GI and ASC groups said the bill would improve access and lower long-term costs, and the bill was reported favorably with amendments. The committee spent the most time on HB 182 by Rep. Travis Johnson, which would require hospitals to ensure access to sexual assault forensic exams and related training. Johnson, law enforcement witnesses, and the Attorney General’s office emphasized the need for timely evidence collection, especially in rural areas, and said the current system leaves victims traveling long distances or losing evidence. Hospital and coroner witnesses supported the goal but opposed the bill as written, arguing it could impose duties on hospitals without enough trained personnel, funding, or a workable statewide training and coordination system; they urged a statewide coordinator, mobile SANE units, and clearer implementation. The bill was not finally disposed of in the portion of the meeting provided, and members discussed continuing to work on amendments and timing before floor consideration.

Transcript Highlights:

• The Hawaii Pharmacists Association is in support. Hi, Chair, Vice Chair, members of the committee.
• Andrews, executive director of the Hawaii Pharmacists Association.

Bills: SB2607, SB2031, SB2043, SB2623, SB2876, SB2396, SB2964, SB2089

Keywords: landscape architecture, licensure, educational requirements, examination, professional standards, consumer protection, junk fees, live-event tickets, short-term lodging, transparency, pricing disclosure, deceptive practices, insurance, captives, regulations, policyholders, SB2623, Hawaii pharmacy law, Board of Pharmacy, registered pharmacy technician

Summary: The committee first heard HCR 168 and HR 158, which would create a temporary working group to study utility capacity, coastline infrastructure lifespan, and the costs of needed expansions. Public Utilities Commission staff said the commission was not the right entity to direct all of the work because it lacks authority over many affected agencies. Members discussed whether the study should be limited to a coastal area or broadened to the whole island, and in decision-making the committee amended the measure to focus on the County of Honolulu, correct references to the Public Utilities Commission, and revise the working group membership to include the PUC chair, legislative designees, and directors or designees from DLNR, DOT, HIEMA, and DCCA Consumer Advocacy. The committee then passed both resolutions with amendments; the vote was adopted unanimously, with some members excused. The committee next considered HCR 145 and HR 137, which would convene a working group on climate change impacts on insurance availability and affordability. The Insurance Division stood on its written comments, the Climate Change Mitigation and Adaptation Commission supported the intent, and the Attorney General opposed the measure, warning that a working group could create discoverable materials that might complicate the state’s climate litigation and noting a technical ambiguity in the reference to the Hawaii Hurricane Relief Fund administrator. After questions about discovery and the lawsuit, the committee amended the resolutions to replace the administrator reference with the chair of the Hawaii Hurricane Relief Fund Board of Directors, remove the Attorney General as convener while keeping the office as a member, and have the working group share findings and recommendations with the House CPC and Senate CPN committees instead of issuing a report. The committee passed the measures with amendments, with Rep. Martin voting with reservations. In the later agenda, the committee heard SB 2607, SD 1 on landscape architect licensure. The Board of Professional Engineers, Architects, Surveyors, and Landscape Architects supported the bill, explaining it modernizes licensure requirements to align with national standards and clarifies the profession’s design-focused role. The bill was discussed as distinguishing landscape architecture from groundskeeping and from civil engineering drainage work. No opposition was heard. The committee also heard SB 2031, SD 2 on consumer protection and price transparency for live ticket events and short-term lodging. The Office of Consumer Protection supported the bill, saying it largely mirrors an FTC rule requiring all-in pricing and would give the state enforcement authority and remedies. The Hawaii Financial Services Association opposed the bill as drafted and sought a limited exemption for credit card issuers relying on third-party hotel information, while the Hawaii Hotel Alliance supported the measure but asked for language deeming compliance with the federal rule sufficient for short-term lodging. Committee members questioned whether those proposed exemptions would conflict with federal law or weaken state enforcement, and the discussion focused on preemption, liability, and the value of state remedies such as restitution.

Transcript Highlights:

• It also states that a PBM may only recoup a dispensing fee if a pharmacist made a clerical error that
• Members, we do have a few pharmacists who may be here to testify.
• On behalf of pharmacists across the country, thank you.
• My name is Sean Sams, I'm a pharmacist.
• This is just a bill that's going to help our local independent pharmacists that...

Bills: HB1464, HB1635, HB2516, HB3317, HB3502, HB4012, HB4268, HB4386, HB4877, SB916

Keywords: prescription drugs, drug pricing, pharmacy benefits, health insurance, health benefit plan, insurer, HMO, self-insured employer, public employer, school district, county, municipality, university system, higher education, retirees, dependent coverage, stop-loss coverage, bulk purchasing, group purchasing, purchasing pool

Transcript Highlights:

• This Ishawnda Lassiter has been a pharmacist for years in the Dell City area.
• Hello, thank you for allowing me to be here and have the honor of having my father, who's a pharmacist
• And, you know, CVS is there's a group of pharmacists in Rhode Island that have gotten together kind of
• It doesn't create prescriptive authority; it just updates the pharmacy act so pharmacists can legally
• Medical law said they met that medical law said they could prescribe.

Bills: HB3767, HB3934, HB4199, HB4336, HB2947, HB3834, HB4302, HB4095, HB3287, HB3649, HB4430, HB4431, HB2059, HB3647

Keywords: controlled dangerous substances, controlled substances, drug scheduling, Schedule I, Schedule IV, anti-drug diversion, drug diversion, synthetic opioids, fentanyl analogs, designer drugs, synthetic cannabinoids, benzodiazepines, benzodiazepine analogs, opioids, hallucinogens, depressants, pharmacy regulation, narcotics control, Oklahoma State Bureau of Narcotics and Dangerous Drugs Control, DEA scheduling

Transcript Highlights:

• I'm a pharmacist and I lead the Minnesota medication pass-through program, also known as Roundtable Rx
• The pharmacist let us choose between a handful of different flavors.
• community pharmacist for life.
• They have provided guidance for pharmacists who are not registered.
• Compounding pharmacists can flavor medicines if certain conditions are met.

Bills: HF3454, HF3917, HF2906, HF3832, HF3769

Keywords: social work, licensure, employment titles, health occupations, professional standards, medication repository, drug donation, healthcare, Minnesota Statutes, pharmacy, public health, controlled substances, psilocybin, psilocin, psychedelic, psychedelic medicine, hallucinogen, mushrooms, magic mushrooms, therapeutic use

Transcript Highlights:

• less prescribed opioids out there.
• The first is the average number of opioid pills prescribed at discharge.
• They were prescribing 36 pills before the Billion Pill Pledge Program, before we got started.
• Now they're prescribing about 13. Next metric is how many of those pills are used?
• So they're getting prescribed 13 on average. They're using five. That means eight leftover pills.

Summary: The committee first approved the previous meeting minutes and then heard a detailed annual report from Dr. Thomas Arnold, chair of the Maternal Mortality Review Committee, on maternal mortality trends and policy issues. He explained the committee’s review process, confidentiality protections, and national and North Dakota data showing that most maternal deaths are preventable and that mental health conditions, substance use, cardiovascular issues, infection, hemorrhage, and embolism are the leading causes. Members asked about suicide, domestic violence, midwife training, home births, and whether pregnancy testing at death scenes should be expanded; Dr. Arnold said better coroner education, more investigation of unexplained deaths, and possible post-mortem pregnancy testing could improve case identification, especially in rural areas. He also noted that deaths often occur well after 42 days postpartum and that mental health-related deaths remain a major concern. The committee then heard from State Fire Marshal Dr. Matthew Clark on cigarette reduced-ignition-propensity standards and related fire prevention issues. He recommended updating the state’s cigarette propensity law to current national standards and also raised a separate recommendation to require fast-breakaway oxygen tubing for home oxygen users, citing fatal fires linked to smoking around oxygen. Members asked about implementation, cost, insurance coverage, and whether the standards apply in tribal communities; Dr. Clark said he would provide follow-up information and was willing to help with any legislation, but no agency bill had yet been planned. Next, Christine Greff of the Department of Health and Human Services reported on the North Dakota Stroke System of Care. She described the statewide network of stroke-ready hospitals, registry-based quality improvement, and performance data showing continued improvement in stroke recognition, imaging, thrombolytic treatment, transfers, and EMS pre-notification. She highlighted new quality measures for inter-facility transfers and intracerebral hemorrhage care, and said the system remains strong but depends on continued legislative and hospital support. Committee members asked about participation by the VA hospital and were encouraged to consider outreach to include it more fully in the stroke system. Finally, the committee began a presentation on prior authorization and non-opioid pain treatment from Taha Khan of Vertex Pharmaceuticals. He argued that prior authorization can delay access to non-opioid acute pain medications, especially in the 24- to 72-hour post-discharge window when pain is most severe, and said delays can push patients toward opioids. He emphasized that prior authorization has a role in utilization management but should not create barriers in acute pain care, and he noted that current use of the company’s non-opioid product remains very low. The discussion was still underway when the transcript ended.

Transcript Highlights:

• We have potentially 26,000 or so prescribers in this state that can prescribe this medication, but only
• ><c> so</c><00:46:43.760><c> prescribers</c><00:46:44.280><c> in</c> potentially 26,000 or so prescribers
• prescribe this this state that can prescribe this medication<00:46:46.839><c> about</c><00:46:47.119
• about two or 3,000 prescribe medication about two or 3,000 prescribe it<00:46:48.640><c> right</c><00
• </c><00:48:14.800><c> this</c> physicians comfortable prescribing this physicians comfortable prescribing

Keywords: 00:00:00 Call to Order/Roll Call 00:01:19 Discussion of 25RS HB 785 00:30:25 Roll Call Vote on 25RS HB 785 00:32:15 Discussion of 25RS HB 61 00:36:42 Roll Call Vote on 25RS HB 61 00:38:07 Discussion of 25RS HB 788 00:51:01 Discussion of 25RS SB 14 01:11:09 Discussion of 25RS HB 685 01:44:57 Adjournment, 958, all

Summary: The House Standing Committee on Health Services met with a quorum and took up House Bill 785, as amended by a committee substitute that combined language from HB 785 and HB 787. The bill was described as addressing Medicaid managed care organization (MCO) audits, provider contract notice and amendment procedures, mental health parity compliance, and related transparency requirements. Supporters said the measure would tighten notice to providers, limit repeated contract amendments and rate reductions, require more standardized audit procedures, and add reporting on Medicaid claims, appeals, and grievances. It also includes a provision requiring coverage of at least two evaluation-and-management billable services per physician per recipient per date of service, and a section addressing narcotic/opioid treatment program licensing and reimbursement language. Testimony in support came from Representative Kim Moore, John Inman of BrightView Health, Michelle Sandborne of the Children’s Alliance, and Kelly Cormic of RYSE. They argued that MCOs often use audits and recoupments in ways that are burdensome, opaque, and financially damaging to providers, especially smaller and rural ones. They cited examples of multiple audit requests in short timeframes, large record requests with short deadlines, delayed or absent feedback, and recoupments taken before appeals are resolved. They also said parity laws are not being consistently enforced and that the bill would give the Department of Insurance authority to suspend or revoke an MCO certificate of authority for willful or repeated parity violations. Committee members generally expressed support for provider protections and transparency, while asking for clarification on the narcotic treatment and E/M billing provisions. Tom Stevens of the Kentucky Association of Health Plans testified in opposition, saying the bill is complex to implement and should be handled through the broader Medicaid oversight work of House Bill 9, the MOAB. He said the issues raised were better suited for that bipartisan stakeholder process and noted the committee substitute had not yet been fully reviewed by his group. After discussion, the committee adopted the committee substitute and then moved to a vote on the bill; the roll call began, with several members recorded as voting yes, but the transcript cuts off before the final vote result is shown.

Transcript Highlights:

• . >> Hey, I'm Anna Catherine Lambert and I'm a pharmacist with the Mississippi State Department of Health
• Even a pharmacist has trouble pronouncing all these.
• 00:03:01.800><c> tazenes,</c><00:03:02.440><c> even</c><00:03:02.640><c> a</c><00:03:02.680><c> pharmacist
• </c><00:03:03.120><c> has</c> the tazenes, even a pharmacist has the tazenes, even a pharmacist has trouble
• is approved during the lapse, this would put, I guess, the drug in a position where it could be prescribed

Keywords: Drug Policy - Room 409, 26 February, 2026; 2:30 P.M., 925, all

Transcript Highlights:

• And this one talks about prescriptive authority for pharmacists and therapeutic substitution.
• This one talks about prescriptive authority for pharmacists and therapeutic substitution.
• in place for some time, which means that a limited number of treatments would be possible for a pharmacist
• brought up the fact that it would be better to have exclusions for the list of things that the pharmacist
• very difficult to have a complete list of inclusions, but you could specifically exclude ones that pharmacists

Keywords: 908, all

Summary: The Health Care Task Force reconvened to hear reports from its divisions. The Appropriations Division reviewed a draft bill appropriating $198 million in federal grant funds for the current year and another $198 million for the next grant year, authorizing DHS to transfer funds within its budget, allowing OMB to adjust federal fund authority for related grants, speeding procurement and bulk purchasing, requiring grant recipients to acknowledge the temporary nature of the funding, and mandating periodic reporting. After questions were answered to the division’s satisfaction, the committee voted to forward the appropriations bill draft to Legislative Management. The Policy Division then reviewed four bills. One would require the presidential physical fitness test to be included in high school physical education; another would require physicians to complete one hour of continuing education on nutrition and metabolic health each renewal cycle; a third would add physician assistants to the interstate licensure compact framework; and a fourth would authorize limited pharmacist prescriptive authority and therapeutic substitution. Members generally supported the first three measures and noted that the pharmacist bill had been amended in discussion but was left in its current form so stakeholders could comment before the special session. The division also discussed that all four policy bills were tied to the federal grant funding and that failure to pass them, or changing them in a way that reduced CMS scoring, could reduce or eliminate funding. Department officials confirmed that if any of the bills failed or were altered in a way that lowered the score, the state could lose money and could not make up the points elsewhere. Members raised concerns about the physical fitness bill, including possible exemptions for students with severe illnesses or physical limitations, and noted the need for DPI input. Leadership indicated the special session hearings would likely begin Wednesday morning. The committee then approved a motion for Legislative Council to prepare a committee report for Legislative Management and adjourned, noting the task force may need to remain available during the special session.

Transcript Highlights:

• Pre-authorization is when your healthcare provider prescribes a medication to you that is not on the
• who have to go through extra schooling in order to do any kind of prescribing.
• Alejandro Amparo, who is with OSI and is a pharmacist, and Dr.
• The pharmacist, Dr. Alejandro, would like to comment on this. He's online. Sure, please, Dr.
• I am not A prescriber, but I have spoken to many of them, and there is a difference.

Bills: SB20, SB53, SB86, SB96, SB129

Keywords: prior authorization, pharmacy benefits manager, PBM, health insurer, prescription drugs, step therapy, formulary, auto-adjudication, electronic portal, appeals, medical necessity, serious mental illness, mental health, schizophrenia, bipolar disorder, major depression, substance use disorder, addiction treatment, cancer, autoimmune disorder

Transcript Highlights:

• GENERICS MAKE UP 90% OF PRESCRIPTIONS PRESCRIBED WOULD ONLY REPRESENT 15 TO 20% OF SALES. 10% REALLY
• IT IS AN INSULT TO THE PHARMACIST WHO WENT TO GRADUATE SCHOOL TO MAKE SURE THEY DISTRIBUTE PRESCRIPTION
• SO THE TRUTH OF THE MATTER IS WHY ARE INDEPENDENT PHARMACIST FORCED TO LOSE MONEY ON A PRESCRIPTION
• INDEPENDENT PHARMACISTS WOULD LIKE TO SEE SOME IMPROVEMENTS IN THE BILL, THERE'S FIVE THINGS AND I WILL
• NUMBER THREE ALLOW OIR TO PUT CONSUMERS AND PHARMACIST COMPLAINTS ON THEIR HOMEPAGE.